Background. 9mTc-methoxyisobutyl isonitrile (Sestamibi) is a new perfusion agent that has shown
tion is proportional to myocardial blood flow. 5, 6 The intracellular extraction of this radionuclide is less dependent on active transport mechanisms compared with 2`'Tl.7 8 Cellular uptake and retention of Sestamibi are dependent on mitochondrial and plasma membrane potentials.9-'2 Sestamibi remains relatively fixed in myocardial cells after initial extraction and demonstrates minimal delayed redistribution.5,13,14 When administered during coronary artery occlusion, the myocardial uptake of Sestamibi correlates with occlusion flow and reflects the "area at risk."'15"6 When administered 90 or more minutes after reperfusion preceded by sustained coronary occlusion, the pattern of myocardial Sestamibi activity reflects myocardial viability more than reperfusion flow.'6 These data and other experimental observations '7-20 have indicated that Sestamibi may be a valid marker of myocardial cellular viability.
The overall objective of the current investigation was to better define myocardial Sestamibi uptake and retention after reperfusion in dogs undergoing 3 hours of coronary occlusion and to determine if myocardial 9'Tc-Sestamibi retention is a marker of viability. The specific hypotheses tested in this study were that if Sestamibi is given early after reperfusion and myocardial uptake is quantitated soon afterward, the degree of ultimate myocardial salvage will be overestimated; and there will be continued loss of Sestamibi during 3 hours of reperfusion due to accelerated release of Sestamibi from cells irreversibly injured during the phase of coronary occlusion, reperfusion injury to myocytes still viable early after reflow, or both.
Methods

Surgical Preparation
Experiments were performed in 43 fasted adult mongrel dogs that were anesthetized with sodium pentobarbital (30 mg/kg), intubated, and ventilated on a respirator (Harvard Apparatus, South Natick, Mass.) with 4 cm of positive end-expiratory pressure. Arterial blood gases were monitored with levels maintained at physiological ranges. Lead II of the ECG was continuously monitored. The right femoral vein was cannulated with an 8F polyethylene catheter for administration of fluids, medications, and 99ITc-Sestamibi. Both femoral arteries were isolated and cannulated with 8F polyethylene catheters, and they were used for collection of arterial blood samples and microsphere reference blood withdrawal. A 7F catheter was placed in the right femoral artery for continuous monitoring of arterial blood pressure.
The basic open-chest canine model used in these experiments has been previously described. 16 Briefly, a thoracotomy was performed at the level of the fifth intercostal space, and the heart was suspended in a pericardial cradle. A flare-tipped polyethylene tube was inserted into the left atrium via the left atrial appendage for continuous pressure measurement and injection of radiolabeled microspheres. For experiments in which coronary sinus sampling was performed, the left jugular vein was exposed, and a 7F coronary angiographic catheter (Cordis, Miami, Fla.) was advanced through the right atrium and into the coronary sinus until its tip rested in close proximity to the left anterior descending coronary artery (LAD). An approximate 1.5-cm segment of the LAD was dissected free of the epicardium, and an ultrasonic flow probe (T201, Transonic Systems, Inc., Ithaca, N.Y.) and a snare ligature were placed around the vessel.
All experiments were performed with the approval of the University of Virginia Animal Research Committee in compliance with the position of the American Heart Association on the use of research animals. Figure 1 .
Determination of Regional Myocardial Blood Flow With Radioactive Microspheres
The technique for assessment of regional myocardial blood flow by the radioactive microsphere technique has been previously described.16 A dose of spheres (2-5 million; mean diameter, 11 ,um) was suspended in 10% dextran and Tween 80. Normal saline was added to bring the total volume to 3 mL. Uniform mixing was accomplished initially by mechanical agitation (Vortex Genie mixer, Scientific Products) and followed by backand-forth hand agitation between two syringes attached to a three-way stopcock. The Hemodynamics. Heart rate remained stable for the duration of the protocol in groups I and II. In group I, arterial blood pressure remained constant throughout the experiment, whereas in group II, mean aortic pressure fell slightly during the 180 minutes of reflow. In group I dogs, LAD flow was 19±1 mL/min at baseline and fell to 0 mL/min with LAD occlusion. Peak LAD flow measured at 1 minute after release of the occlusion was 60±12 mL/min (p=0.0001 versus baseline). Mean LAD flow at the time of 991Tc-Sestamibi administration at 2-5 minutes of reflow was 46±4 mL/min (p=0.001 versus baseline). In group II dogs, mean LAD flow was 25 ± 1.5 mL under baseline conditions, fell to 0 mL/min during total LAD occlusion, and increased to 55±9 mL/min at 1 minute after reflow (p=0.001 versus baseline). Mean LAD flow at the time of 9'Tc-Sestamibi injection at 2-5 minutes after reflow was 40±3 mL/min, comparable to flow in group I dogs at the time of 9'Tc-Sestamibi injection.
Relation between myocardial distribution of Sestamibi and regional myocardial blood flow. Figures 2A and 2B summarize mean values for occlusion flow, reperfusion flow, and Sestamibi activity in the central ischemic zone in the seven group I dogs and the nine group 2 dogs, respectively. Values are shown for endocardial and transmural regions for each group. As summarized in Figure 2A , flow in the endocardial region during occlusion in group I dogs was 9±2% of nonischemic flow, significantly less than the transmural occlusion flow, which was 20±3% of nonischemic flow (p=0.0005). Reperfusion flow in the ischemic region at the time of Sestamibi injection (2-5 minutes after reflow) was 144±23% of nonischemic flow in the endocardial region, not significantly different from the corresponding mean transmural flow during reperfusion (166±14% of nonischemic flow). Mean endocardial Sestamibi activity in group I dogs was 74±4% of nonischemic activity, and transmural activity was 75±3% of nonischemic activity (p=NS). 3 hours of occlusion and 3 hours of reflow had no significant change in heart rate after occlusion. As is typical for 3-hour occlusion experiments, there was a tendency for arterial blood pressure to fall and left atrial pressure to rise over the occlusion time period in all groups. The ultrasonically measured LAD flow fell to 0 mL/min during occlusion. As shown in Table 1 , reperfusion was documented in all three groups with the ultrasonic flow probe. Group I dogs killed 4 minutes after reperfusion demonstrated higher flow values during reperfusion than the other two groups. Because these animals were killed at 4 minutes after reperfusion, flows remained in the hyperemic range.
Regional myocardial blood flow values. Regional blood flow values at baseline (when Sestamibi was injected), during occlusion, and during reperfusion just before termination of the experiment are summarized in Table  2 . Endocardial and transmural flows are depicted for the nonischemic LAD region proximal to the occlusion, in the severely ischemic region where flow during occlusion was less than 30% of nonischemic flow, and in the mild-to-moderate ischemic region where flow was reduced during occlusion to 31-80% of nonischemic flow. Endocardial and transmural flows at baseline were comparable in all three regions of the heart. During coronary occlusion, flow was reduced to approximately 50% of nonischemic flow in the mild to moderate ischemic region and to 10% or less of nonischemic flow in the most severely ischemic region. After reperfusion, endocardial and transmural flow from severely ischemic and mild to moderate ischemic regions were hyperemic in group I dogs killed 4 minutes after reperfusion.
Coronary sinus sampling. The graph in Figure 4 displays the coronary sinus Sestamibi values, expressed as percentage of its corresponding arterial sample during the time of the experimental protocol. Each value on the graph represents an average from all dogs from all three groups at that time point. As shown, a minimal amount of Sestamibi appeared in the coronary sinus blood throughout the occlusion period. After reflow, there was an instantaneous transient increase in Sestamibi activity, which was followed by a sustained elevation of activity during the 3 hours of reperfusion. The coronary sinus Sestamibi activity after 180 minutes of reflow remained substantially elevated compared with arterial Sestamibi activity. These data are consistent with a continuous net efflux of Sestamibi from the myocardium into the coronary venous effluent during reperfusion.
Sestamibi retention after 3 hours of coronary occlusion and varyingperiods ofreperfusion. The mean normalized endocardial and transmural Sestamibi myocardial tissue activities in normal and ischemic regions in groups I-III In all three groups in this protocol, Sestamibi was preloaded by intravenous injection under baseline conditions before occlusion of the LAD. Note that in group I and group II dogs undergoing 3 hours of occlusion and 4 minutes and 30 minutes of reperfusion, respectively, after 9'Tc-Sestamibi loading ( Figures 5 and 6) , activity of the radionuclide was significantly reduced in ischemic zones compared with nonischemic activity. However, the loss of myocardial 99mTc-Sestamibi was significantly greater at 3 hours of reperfusion (group III) compared with 4 minutes (group I) and 30 minutes (group II) after reflow. In the 10 group III dogs preloaded with 'mTcSestamibi at baseline, 3 hours of occlusion followed by 3 hours of reflow resulted in a loss of 99mTc-Sestamibi in the endocardial zone of the severely ischemic region to 40±6% of nonischemic and in the transmural region as 51±5% of nonischemic ( Figure 7 ). By ANOVA, there was a highly significant difference among groups I-III (p=0.003) in endocardial Sestamibi activity after reperfusion in the severely ischemic region. By unpaired t testing, there was no difference in activity between the 4-and 30-minute reperfusion groups but significant differences between 4-minute and 3-hour reperfusion groups (p=0.002) and between 30-minute and 3-hour reperfusion groups (p=0.012). Similar significant differences by ANOVA were seen among the three groups Gamma camera imaging of defect magnitude. Figure 8 summarizes the defect magnitudes determined from the image count ratio of the LAD to the left circumflex region. Note that the mean defect magnitude in group III dogs undergoing 180 minutes of reperfusion was significantly greater than the defect magnitude in the group I and group II dogs, which underwent 4 minutes and 30 minutes of reperfusion, respectively. Again, because all dogs in this protocol received 9'9Tc-Sestamibi under normal conditions before coronary occlusion, the greater defect magnitude in group III animals reflected a loss of tissue 9'Tc-Sestamibi as a consequence of reperfusion.
Infarct Size Determinations
Infarct size by TTC staining in group II dogs undergoing 3 33 Thus, the results of both experimental and clinical studies provide evidence that serial Sestamibi imaging provides an accurate assessment of myocardium at risk during coronary occlusion and ultimate infarct size and degree of myocardial salvage with reperfusion. The final defect size will presumably also reflect the degree of injury, if any, induced by reperfusion itself.
Finally, the experimental data reported in the present study yield further evidence that Sestamibi may be a valid viability agent when administered at an appropriate time point during the course of evolving ischemic injury in the setting of reperfusion. Our data confirm that uptake and retention of Sestamibi are not solely dependent on regional blood flow but also on myocardial cellular integrity. This conclusion is supported by the observation that when 'Tc-Sestamibi was loaded in the myocardium under normal baseline conditions, subsequent prolonged ischemia and reperfusion resulted in a progressive loss of Sestamibi from myocardial tissue. This cumulative loss yielded a defect comparable in severity to that seen when Sestamibi was first administered after the same duration of coronary occlusion (3 hours) and reflow (3 hours). These data support the hypothesis that necrotic cells can neither extract nor retain Sestamibi.
Implications of the Present Study
There are some relevant clinical implications to the observations made in the present experimental study. First, if Sestamibi is administered soon after reperfusion and imaging is performed within 30 minutes, the degree of myocardial salvage could be overestimated and infarct size will be underestimated. Data from this study show that when Sestamibi is administered immediately after reflow, defect magnitude is less and myocardial activity is substantially higher than when quantitated 3 hours later. Therefore, a rapid radionuclide imaging protocol aimed at assessing the efficacy of reperfusion soon after administration of a thrombolytic agent with Sestamibi may yield misinformation. These observations are similar to those made when 20`T1 is administered soon after reperfusion, resulting in overestimation of degree of salvage.34 '35 The present experimental studies also demonstrate a considerable loss of Sestamibi over 3 hours of reflow, perhaps secondary to accelerated egress of Sestamibi from cells irreversibly injured during the phase of occlusion, some reperfusion injury, or both. A delay of at least 2-3 hours after restoring vessel patency before administering Sestamibi to noninvasively assess the amount of ultimate myocardial salvage would seem appropriate. If 99"Tc-Sestamibi is administered soon after restoring blood flow, then a delay of at least 2-3 hours should be instituted before commencing imaging to accurately determine degree of myocardial salvage. Imaging at that time point would provide more accurate information pertaining to infarct size.
